CART19

CART19 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为SLE、Systemic Lupus Erythematosus (SLE)、CAR T Cell、CART19。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 CART19 研究

• CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

  I 期招募中CzechiaNCT05054257

• Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma

  I 期招募中美国NCT07676877

• CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

  I 期 / II 期招募中美国NCT06839976

• Orphan Indications for CD19 Redirected Autologous T Cells

  II 期招募中美国NCT04276870

• Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

  I 期 / II 期招募中美国NCT05480449

• CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma

  I 期 / II 期招募中BrazilNCT06101381

• Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

  II 期招募中美国NCT05633615

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。